[go: up one dir, main page]

AR011057A1 - Uso de bis-acridinas sustituidas y compuestos afines para la preparacion de medicamentos y dichos compuestos - Google Patents

Uso de bis-acridinas sustituidas y compuestos afines para la preparacion de medicamentos y dichos compuestos

Info

Publication number
AR011057A1
AR011057A1 ARP980100032A ARP980100032A AR011057A1 AR 011057 A1 AR011057 A1 AR 011057A1 AR P980100032 A ARP980100032 A AR P980100032A AR P980100032 A ARP980100032 A AR P980100032A AR 011057 A1 AR011057 A1 AR 011057A1
Authority
AR
Argentina
Prior art keywords
4alkyl
alkyl
independently
cycloalkyl
compounds
Prior art date
Application number
ARP980100032A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR011057A1 publication Critical patent/AR011057A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D219/00Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08Nitrogen atoms
    • C07D219/10Nitrogen atoms attached in position 9
    • C07D219/12Amino-alkylamino radicals attached in position 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere al uso de bis-acridinas sustituidas de formula (I) o una sal farmacéuticamente aceptable del mismo: formula (I) en la que: los X sonindependientemente uno o más de H, alquilo C1-6 opcionalmente sustituido, cicloalquil C3-7-alquilo C0-4, AR-alquilo C0-4, CH2NR2, CH2OR, CN, COR,CONR2, CO2R,CF3, N(R)2, NRCOR, NRCONRR, NRCO2R, NRSO2R, NO2, OR, S(O)0-2R, S(O)0-2CF3, o halo; R1 es H, alquilo C1-6 opcionalmente sustituido,cicloalquil C3-7-alquilo C0-4 o Ar-alquilo C0-4; R es alquilo C1-6, cicloalquil C3-7-alquilo C0-4 o Ar-alquilo C0-4; D y Dson independientementeCX o N; V y V son independientemente C(R)2, NR1 O, S(O)0-2; los R1 son independientemente H, alquilo, C1-6, cicloalquil C3-7-alquilo C0-4 Ar-alquiloC0-4, -C(O)CF3, -C(O)R o -SO2R o, cuando V y V son -NR1, los dos grupos R1 tomados conjuntamente pueden ser (C(R)2)2-3 para formar un anillo heterocíclicode 5 a 9 miembros; n es 0, 1, 2 o 3; y los R son independientemente H, alquilo C1-6, cicloalquil C3-7-alquilo C0-4 o Ar-alquilo C0-4 o, cuando V y V sonindependientemente NR1, O o S (O)0-2, cualesquiera dos grupos R tomados conjuntamente pueden ser (C(R)2)2-4 para formar un anillo carbocíclico de 3hasta 8 miembros, para la preparacionde un medicamento util para tratar un estado de enfermedad mediado por CCR5 en mamíferos, que comprende una cantidadeficaz de dicho compuesto y al menos un vehículo farmacéuticamente aceptable. Estos compuestos afines son ligandos, en particular antagonistas del receptorCCR5, que incluyen, pero no se limitan a, asma y enfermedades atropicas (por ejemplo, dermatitis atopica y alergias), artritis reumatoide, aterosclerosis,psoriasis, enfermedades autoinmunitarias tales como la esclerosismultiple y el síndrome de intestino inflamatorio, todas ellas en mamíferos, por el uso de bis
ARP980100032A 1997-01-08 1998-01-05 Uso de bis-acridinas sustituidas y compuestos afines para la preparacion de medicamentos y dichos compuestos AR011057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3514897P 1997-01-08 1997-01-08

Publications (1)

Publication Number Publication Date
AR011057A1 true AR011057A1 (es) 2000-08-02

Family

ID=21880954

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100032A AR011057A1 (es) 1997-01-08 1998-01-05 Uso de bis-acridinas sustituidas y compuestos afines para la preparacion de medicamentos y dichos compuestos

Country Status (9)

Country Link
US (2) US6242459B1 (es)
EP (1) EP0979078A4 (es)
JP (1) JP2001509152A (es)
AR (1) AR011057A1 (es)
AU (1) AU6020898A (es)
CA (1) CA2276525A1 (es)
CO (1) CO4920243A1 (es)
WO (1) WO1998030218A1 (es)
ZA (1) ZA9895B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6514987B1 (en) * 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
ZA985542B (en) 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
CN1279668A (zh) 1997-11-18 2001-01-10 帝人株式会社 环胺衍生物及其作为药物的用途
EP1179341B1 (en) 1999-05-18 2005-11-09 Teijin Limited Remedies or preventives for diseases in association with chemokines
WO2000076982A1 (en) * 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
CA2378499A1 (en) 1999-08-04 2001-02-15 Teijin Limited Cyclic amine ccr3 antagonists
ATE346042T1 (de) * 1999-12-08 2006-12-15 Teijin Ltd Zyklische aminverbindungen als ccr5-rezeptor antagonisten
US6410566B1 (en) 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
JP2004510706A (ja) 2000-07-07 2004-04-08 キャンサー・リサーチ・テクノロジー・リミテッド 治療用アクリドン及びアクリジン化合物
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
AU2003207646C1 (en) * 2002-01-22 2008-09-18 Vanderbilt University Treating stress response with chemokine receptor CCR5 modulators
WO2004005464A2 (en) * 2002-07-02 2004-01-15 Uab Research Foundation Compounds promoting delivery of genes
CA2559809A1 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Antibodies against human g-protein chemokine receptor (ccr5) hdgnr10
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US10149830B2 (en) 2016-06-03 2018-12-11 Cushing Academy Pharmaceutical agents and methods relating thereto
CN115443133B (zh) 2020-02-19 2024-02-20 伊契洛夫科技有限公司 改进的抗抑郁疗法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
WO2024119148A1 (en) * 2022-12-02 2024-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Topoisomerase iii (top3) inhibitors and antiviral compounds based on bisacridines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2503899A (en) * 1945-08-29 1950-04-11 Dow Chemical Co Diacridyl diamine derivatives
FR2314165A1 (fr) 1975-06-13 1977-01-07 Anvar Nouveaux bis (anthryl-9) alcanes et leur preparation
FR2588259B1 (fr) 1985-10-04 1988-01-22 Aix Marseille Universite Bis-acridiniques monopontes et bis-acridiniques bipontes
JPH0688924B2 (ja) 1986-05-28 1994-11-09 ダイセル化学工業株式会社 光記憶材料
DE4014421A1 (de) * 1990-05-05 1991-11-07 Merck Patent Gmbh Aminosaeurederivate
JPH04226467A (ja) 1990-09-13 1992-08-17 Ricoh Co Ltd 電子写真感光体の疲労回復方法
ES2107557T3 (es) * 1991-12-10 1997-12-01 Shionogi & Co Derivado de acido hidroxamico a base de sulfonamida aromatica.
DE4405378A1 (de) * 1994-02-19 1995-08-24 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten

Also Published As

Publication number Publication date
US20010031763A1 (en) 2001-10-18
WO1998030218A1 (en) 1998-07-16
EP0979078A1 (en) 2000-02-16
US6242459B1 (en) 2001-06-05
EP0979078A4 (en) 2000-06-21
CA2276525A1 (en) 1998-07-16
ZA9895B (en) 1998-07-08
CO4920243A1 (es) 2000-05-29
AU6020898A (en) 1998-08-03
JP2001509152A (ja) 2001-07-10

Similar Documents

Publication Publication Date Title
AR011057A1 (es) Uso de bis-acridinas sustituidas y compuestos afines para la preparacion de medicamentos y dichos compuestos
US6190691B1 (en) Methods for treating inflammatory conditions
BR0010304A (pt) Derivados de piperazina úteis como antagonistas do ccr5
ECSP941156A (es) 3 bencilaminometil piperidinas substituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines
MY123865A (en) Novel heterocycles as inhibitors of leucocyte adhesion and as vla-4 antagonists
DE69405862D1 (de) Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten
BR0010607A (pt) Derivados de piperidina úteis como antagonistas de ccr5
ATE250577T1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
DK1060163T3 (da) Nye piperazinyl-substituerede pyridylalkan-, -alken og -alkyncarboxamider
MY119617A (en) 5-membered ring heterocycles as inhibitors of leucocyte adhesion and as vla-4 antagonists
KR920004396A (ko) 42-옥소라파마이신
UA122065C2 (uk) 5-[(піперазин-1-іл)-3-оксопропіл]-імідазолідин-2,4-діонові похідні як інгібітори adamts для лікування остеоартриту
DK556285D0 (da) Tricycloforbindelser
TR199900255T2 (xx) Muskarinik antagonistleri
ID30129A (id) Turunan-turunan tioamida
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
DE69126460D1 (de) Benzisothiazolinon-1-dioxyde als Elastase-Inhibitoren
ES2087038A1 (es) Nuevas piperidinas con actividad antagonista del paf.
EP0937460A2 (en) Use of an antidiarrheal for the manufacture of a medicament for the treatment of inflammatory conditions
ATE264298T1 (de) Alpha-aminoessigsäure derivate als alpha 4 beta 7-rezeptor antagonisten
RU95109159A (ru) Новые биологически активные композиции, их получение и применение
ATE4642T1 (de) 2-hydroxyalkyl-3,4,5-trihydroxypiperidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
AR018505A1 (es) COMPOSICIoN FARMACÉUTICA ANTIHISTAMíNICA CON UN INHIBIDOR DE LA P-GLICOPROTEíNA Y EL USO DE DICHA COMPOSICIoN PARA LA FABRICACIoN DE MEDICAMENTOS PARA AUMENTAR LA BIODISPONIBILIDAD DE DICHO ANTIHISTAMíNICO.
DK93791D0 (da) Nye heterocykliske carboxylsyrer
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação